Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3952-3957

  Suehisa, Hiroshi ^a   Toyooka, Shinichi ^a   Hotta, Katsuyuki ^a   Uchida, Akiko ^a   Soh, Junichi ^a   Fujiwara, Yoshiro ^a   Matsuo, Keitaro ^a   Ouchida, Mamoru ^a   Takata, Minoru ^a   Kiura, Katsuyuki ^a   Date, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; UFT; ANTINEOPLASTIC AGENT; TEGAFUR; URACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE; GENE MUTATION; HAZARD RATIO; HUMAN; IC 50; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WILD TYPE; ADENOCARCINOMA; CELL CULTURE; GENETICS; LUNG TUMOR; MORTALITY; MUTATION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TUMOR CELLS, CULTURED; URACIL;

EID: 34548530411     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8646     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Travis WD, Colby TV, Corrin B, et al: Histological Typing of Lung and Pleural Tumours. Berlin, Germany, Springer, 1999
3. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
4. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
5. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
6. Tanaka F, Miyahara R, Ohtake Y, et al: Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 14:256-262, 1998
7. Hotta K, Matsuo K, Ueoka H, et al: Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22:3860-3867, 2004
8. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004
9. Hamada C, Tanaka F, Ohta M, et al: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006, 2005
10. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
11. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
12. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
13. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005
14. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
15. Ueda M, Kitaura K, Kusada O, et al: Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. Jpn J Cancer Res 91:1185-1191, 2000
16. Magne N, Fischel JL, Dubreuil A, et al: ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: Rational basis for a new combination therapy with capecitabine. Clin Cancer Res 9:4735-4742, 2003
17. Politi K, Zakowski MF, Fan PD, et al: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496-1510, 2006
18. Tanaka F, Otake Y, Yanagihara K, et al: Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 84:263-269, 2001
19. Sobin LH, Wittekind C: TNM Classification of Malignant Tumors (ed 6). New York, NY, Wiley, 2002
20. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167-1173, 2005
21. Uchida A, Hirano S, Kitao H, et al: Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 98:357-363, 2007
22. Toyooka S, Maruyama R, Toyooka KO, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103:153-160, 2003
23. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167, 2004
24. Oki E, Sakaguchi Y, Toh Y, et al: Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours. Br J Cancer 78:625-630, 1998
25. Sequist LV, Joshi VA, Janne PA, et al: Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 12:4403s-4408s, 2006
26. Keicho N, Saijo N, Shinkai T, et al: Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 16:143-146, 1986